Fewer relapses and worse outcomes of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease
Compared with patients with EO-MOGAD, patients with LO-MOGAD exhibited fewer relapsing courses but worse disability outcomes and should be actively treated.
Authors
- Wenjuan Huang (ORCID: https://orcid.org/0000-0002-8056-373X)
- Yuxin Fan (ORCID: https://orcid.org/0009-0006-7784-7340)
- Lei Zhou (ORCID: https://orcid.org/0000-0002-9880-5506)
- Xuechun Chang (ORCID: https://orcid.org/0000-0002-4169-0146)
- Jingzi ZhangBao (ORCID: https://orcid.org/0000-0002-5308-6325)
- Liang Wang (ORCID: https://orcid.org/0000-0003-3010-6845)
- Chao Quan (ORCID: https://orcid.org/0000-0003-1040-3930)
- Ziyi Wang (ORCID: https://orcid.org/0009-0006-2182-326X)
- Yuhang Wu (ORCID: https://orcid.org/0000-0002-4339-0753)
- Hongmei Tan (ORCID: https://orcid.org/0000-0002-3141-7920)
Institutions
- Fudan University (CN)
- University of Minnesota Medical Center (US)
- Huashan Hospital (CN)
Publication Details
- Journal
- Journal of Neurology Neurosurgery & Psychiatry
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1136/jnnp-2024-334613
- Citations
- 5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.12
Funders
- National Natural Science Foundation of China